CJC-1295: separating the mechanism from the hype
A small peptide with a long half-life — and a longer list of overstatements online.
TL;DR
- CJC-1295 is a GHRH analog — a copy of the brain signal that asks the pituitary to release the body's own growth hormone.
- It does not contain growth hormone, and it is not the same as HGH.
- The mechanism is well-described in small human studies, which measured hormone levels. Effects on health outcomes have not been shown in people.
What it is
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone (GHRH, in plain English: the brain's natural "make more growth hormone" signal). Two forms exist. CJC-1295 with DAC carries a drug affinity complex — a tag that lets it persist in the blood for days. CJC-1295 without DAC, sometimes called "Mod GRF 1-29," clears in minutes. Both ask the same pituitary door to open. The difference is how long the request lingers.
How it works
Think of GHRH as the brain telling the pituitary, "Release a growth-hormone pulse now." CJC-1295 is a longer-lasting copy of that note. Without DAC, the note is read once and disposed of, so it would trigger only a short pulse. With DAC, the note hangs on the pituitary's bulletin board for days; in healthy adults, growth-hormone levels stayed raised across that window (Teichman et al., 2006). Neither version replaces growth hormone — both depend on the pituitary being able to respond.
Who asks about it
People come to this topic when they see CJC-1295 listed beside HGH and want to know if it is the same thing (it is not). Others come from forum discussions whose claims go far beyond the published clinical literature, and they want a calmer reference point.
What the research says
Small human studies of GHRH analogs, including CJC-1295 in healthy adults, show a dose-dependent increase in IGF-1 (insulin-like growth factor 1, a downstream marker of growth-hormone activity). Effects on body composition, sleep or other health outcomes have not been shown in people. CJC-1295 with DAC has been studied less in long-duration human trials than its sermorelin cousin — a reason to be honest about the limits of the evidence base.
What to know
Common reported effects include injection-site reactions, a brief head-rush flush, vivid dreams, and water retention. Long-term safety in people has not been established. Compounded CJC-1295 is not FDA-approved. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list.
The Halftime POV
The peptide world is not short on hype. CJC-1295 has a well-described mechanism, but the published human studies are small and measured hormone levels, not health outcomes. We would rather under-promise the mechanism than oversell the marketing.
Related reading:
- CJC-1295 vs sermorelin: comparing two GHRH analogs
- CJC-1295 and ipamorelin: why they are discussed together
- Sermorelin, CJC-1295, ipamorelin, MK-677: a plain-language comparison
FAQ
Q: Is CJC-1295 the same as growth hormone? A: No. CJC-1295 is a copy of the brain signal that tells the pituitary to release the body's own growth hormone. It does not replace growth hormone.
Q: What does the "DAC" in CJC-1295 with DAC mean? A: DAC stands for drug affinity complex. It is a small chemical tag that helps the peptide stay in the bloodstream longer.
Q: Is CJC-1295 FDA-approved? A: No. CJC-1295 is not FDA-approved as a finished drug product. Compounded CJC-1295 is not FDA-approved. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list.
Q: What are common reported side effects? A: Injection-site reactions, a temporary head-rush flush, vivid dreams, and water retention are the most commonly reported. Long-term safety in people has not been established.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
- Teichman SL et al., "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults," J Clin Endocrinol Metab (2006)
- Molitch ME, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline — J Clin Endocrinol Metab, 2011
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Is CJC-1295 the same as growth hormone?
No. CJC-1295 is a copy of the brain signal that tells the pituitary to release the body's own growth hormone. It does not replace growth hormone.
What does the 'DAC' in CJC-1295 with DAC mean?
DAC stands for drug affinity complex. It is a small chemical tag that helps the peptide stay in the bloodstream longer.
Is CJC-1295 FDA-approved?
No. CJC-1295 is not FDA-approved as a finished drug product. Compounded CJC-1295 is not FDA-approved. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list.
What are common reported side effects?
Injection-site reactions, a temporary head-rush flush, vivid dreams, and water retention are the most commonly reported. Long-term safety in people has not been established.
